Table 1 Summary of Preclinical Efficacy of Group I mGlu Receptor Ligands
From: Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
| Â | Positive Symptom Models | Negative Symptom Models | Cognition Models |
|---|---|---|---|
mGlu 1 PAMs | |||
 VU0483605 | No effect on AHL [41] |  |  |
mGlu 1 NAMs | |||
 FTIDC | Reduced methamphetamine hyperlocomotion (MHL) [56] Ameliorated METH-induced deficits in PPI [56] |  |  |
 CFMTI | Reduced MHL and NMDAR antagonist-induced hyperlocomotion (NMDAR-HL) [57] Ameliorated METH and KET-disrupted PPI [57] | Ameliorated MK-801-disrupted social interaction [57] | No effect on object location memory (OLM) [57] |
mGlu 5 PAMs | |||
 CDPPB | Reduced AHL [70] | Attenuated MK-801-induced decrease in sucrose preference [223] | Enhanced learning in Morris water maze (MWM) [72] Attenuated MK-801-induced deficits in cognitive flexibility [224] Improved PCP-induced deficits in novel object recognition (NOR) [225] |
 5PAM523 | Reduced AHL [76] |  |  |
 VU0409551 | Reduced AHL and NMDAR-HL [81] |  | Enhanced contextual fear conditioning (CF) [81] Enhanced NOR [81] Enhanced working memory/executive function in the delayed non-matching to position (DNMTP) task [81] Improved contextual CF deficits in SR−/− mice [81] |